Moderna Inc. stock gains on cancer vaccine progress and strong rally

Moderna Inc. (ISIN US60770K1079) stock closed at USD 154.03 on Nasdaq on September 18, 2026, which marked a 2.56% gain for that trading day and left the shares near their recent highs after a sharp rally driven by cancer vaccine progress according to MarketBeat.

Stock rally follows cancer vaccine data

In recent weeks, Moderna Inc. stock has benefited from convincing Phase 3 data for a personalized cancer therapy, which has triggered what one German-language market commentary described as a spectacular revaluation of the company as investors reassess its long-term pipeline potential according to Finanznachrichten.

Per the latest data snapshot referenced by MarketBeat, the closing price of USD 154.03 on September 18, 2026 implies a market capitalization of about USD 61.50 billion as of that date, highlighting how far the valuation has moved since the stock traded near the mid-100 dollar range earlier in the year.

Analyst targets and loss-making fundamentals

While the share price has rallied strongly, consensus analyst numbers referenced in a recent data overview show that the average price target for Moderna Inc. stock stands at USD 76.72, which is roughly 50.2% below the September 18, 2026 closing level of USD 154.03 according to MarketBeat.

That same overview notes that on a trailing twelve months basis, Moderna has reported earnings per share of negative USD 7.99, underscoring that the company is currently loss-making and that its trailing price-earnings ratio is not meaningful because the denominator is below zero according to MarketBeat.

For investors, the combination of a share price at USD 154.03 on September 18, 2026 and a consensus target of USD 76.72 means that the market valuation currently implies a premium of about 100% over where analysts, on average, see the stock over the medium term as of that data snapshot, while the negative trailing EPS figure of minus USD 7.99 highlights how dependent the story remains on converting pipeline products such as the cancer vaccine program into sustainable revenue and profit streams according to MarketBeat.

Positioning within biotech and recent trading

The recent commentary comparing Moderna and BioNTech notes that after convincing Phase 3 data for a personalized cancer therapy, Moderna has left the pure pandemic-vaccine narrative behind and is now increasingly being valued as an oncology-focused biotechnology company with broader mRNA applications according to Finanznachrichten.

Short-interest and trading-volume figures compiled in the same MarketBeat overview show that the closing price of USD 154.03 on September 18, 2026 followed a day in which the stock fell 2.56% from the prior session on that venue, while alternative data snapshots such as a recent view from the Pluang platform cited in the week’s coverage mention a very similar price of USD 154.04 with a daily change of minus 2.55% for that trading day, indicating that the shares have been volatile but broadly holding in the mid-150 dollar range according to Ad-hoc-news.

Current price level and valuation snapshot

As of the last completed trading day in the available data, Moderna Inc. stock is thus referenced around USD 154.03 on Nasdaq on September 18, 2026, corresponding to a market capitalization of approximately USD 61.50 billion, a trailing twelve months earnings per share of minus USD 7.99 and a consensus analyst price target of USD 76.72 that implies around 50.2% downside from the current level according to Ad-hoc-news.

More news and analyses on Moderna Inc. stock